Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689092 | 1.00 | KDM4E (0.49) | KDM4ECSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL29686936 | 0.86 | CHRNB2 (0.44) | KDM4ECHRNB2CHRNA4MAPTNPC1 | |
| SCHEMBL17749939 | 0.84 | ALDH1A1 (0.44) | KDM4ECHRNB2CHRNA4L3MBTL1HSD17B10 | |
| SCHEMBL6281582 | 0.80 | HTT (0.50) | KDM4ECHRNB2CHRNA4TDP1L3MBTL1 | |
| SCHEMBL11248491 | 0.78 | GPR35 (0.57) | KDM4ECHRNB2CHRNA4TDP1L3MBTL1 | |
| SCHEMBL24776512 | 0.78 | MEN1 (0.40) | USP2CHRNB2CHRNA4HSD17B10MAPT | |
| SCHEMBL24620866 | 0.77 | F7 (0.46) | KDM4EUSP2PIM1PIM2L3MBTL1 | |
| SCHEMBL30973431 | 0.75 | PIM1 (0.42) | KDM4ECSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL31429009 | 0.75 | RAB9A (0.52) | KDM4EL3MBTL1HSD17B10MAPTHPGD | |
| SCHEMBL10513311 | 0.74 | CA2 (0.54) | CHRNB2CHRNA4HPGDHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0277661-A1 | Imidazopyrrolopyridines and condensed derivatives thereof useful in the preparation of herbicidal compounds | AMERICAN CYANAMID COMPANY (US) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885CSNK2A1 607/4885CSNK2A2 711/4885 |
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | KDM4E 1163/4885CSNK2A1 1469/4885CSNK2A2 1840/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | KDM4E 3565/4885CSNK2A1 1260/4885CSNK2A2 1289/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | KDM4E 763/4885CSNK2A1 1829/4885CSNK2A2 2185/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | KDM4E 875/4885CSNK2A1 276/4885CSNK2A2 386/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885CSNK2A1 607/4885CSNK2A2 711/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | KDM4E 4225/4885CSNK2A1 104/4885CSNK2A2 148/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885CSNK2A1 607/4885CSNK2A2 711/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885CSNK2A1 607/4885CSNK2A2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.